Pneumococcal Infections: all 286 studies

Page 1 of 3. Open to participants first (27), then studies with results posted, then the rest; newest registration first within each.

• A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to AdultsRecruitingNCT07794748Phase 3
• A Study to Evaluate 20vPnC in Healthy Chinese InfantsRecruitingNCT07754539Phase 3
• Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and AdolescentsRecruitingNCT07660198Phase 3
• Randomized Controlled Trial Of Text Messages To Increase Pneumococcal Vaccination In Adults In Chile.Enrolling by invitationNCT07659470Not applicable
• A Clinical Trial of the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)Not yet recruitingNCT07648641
• A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.RecruitingNCT07629440Phase 3
• Clinical Trial of the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)RecruitingNCT07600983Phase 1/2
• A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy InfantsRecruitingNCT07573462Phase 3
• Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of AgeRecruitingNCT07348692Phase 3
• Clinical Trial of PCV24 in Infants and Children Aged 2 Months to 5 YearsRecruitingNCT07300644Phase 2
• A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)RecruitingNCT07300267Phase 1
• Serum Collection Study for Assay DevelopmentRecruitingNCT07205289Phase 1
• Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate VaccinesRecruitingNCT07135453Phase 4
• In-depth Analysis of the Immune Responses in the Upper Respiratory Tract in Older Adults Infected or Colonized With Streptococcus Pneumoniae (Spn)RecruitingNCT06998251
• A Phase I Clinical Study to Evaluate the Safety of PCV26 in Individuals ≥60Not yet recruitingNCT06970756Phase 1
• Immunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in AdultsRecruitingNCT06822907Phase 4
• Opportunistic Pneumococcal Immunisation Trial in MALnutritionRecruitingNCT06817421Phase 4
• Clinical Trial of PCV24 in Infants Aged 2-23 MonthsRecruitingNCT06800261Phase 1
• Carriage to Assess Protection of New Pneumococcal Vaccines - PCV15RecruitingNCT06731374Phase 4
• Clinical Trial of 13-Valent Pneumococcal Conjugate VaccineRecruitingNCT06617715Phase 3
• A Phase 3 Study to Evaluate the Immunogenicity and Safety of Minhai's PCV13-DT/TT Vaccine As Compared to Pfizer's PCV13 VaccineRecruitingNCT06608199Phase 3
• Evaluation of Vaccination for Streptococcus Pneumoniae in Adults With an Episode of Invasive Pneumococcal Infection.Not yet recruitingNCT06334185
• A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy PeopleRecruitingNCT06044077Phase 3
• The Effect of AUDIT and Feedback on Pneumococcal Vaccination CoverageNot yet recruitingNCT05920499Not applicable
• Epidemiology and Household Transmission of Streptococcus Pneumoniae and Respiratory Syncytial VirusNot yet recruitingNCT05017519
• Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIVRecruitingNCT04875819Phase 4
• National, Non Interventional Study of Invasive Pneumococcal Disease in Children and NewbornsRecruitingNCT04664556
• A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)CompletedNCT06177912Phase 3Results posted
• A Study to Learn About the Safety and Immune Response of 20vPnC in Adults in India.CompletedNCT05875727Phase 3Results posted
• A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIVCompletedNCT05794191Results posted
• Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)CompletedNCT05696080Phase 3Results posted
• Safety and Immunogenicity of V116 in Vaccine-naïve Japanese Older Adults (V116-009, STRIDE-9)CompletedNCT05633992Phase 3Results posted
• Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10)CompletedNCT05569954Phase 3Results posted
• Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of AgeCompletedNCT05489328Phase 1Results posted
• A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)CompletedNCT05464420Phase 3Results posted
• Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3)CompletedNCT05425732Phase 3Results posted
• A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy InfantsCompletedNCT05412030Phase 2Results posted
• Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13CompletedNCT05408429Phase 3Results posted
• Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)CompletedNCT05393037Phase 3Results posted
• A Study to Describe the Safety of a Vaccine (Called 13vPnC) in Healthy People 18 to 49 Years of Age in IndiaCompletedNCT05329259Phase 4Results posted
• Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)CompletedNCT05158140Phase 3Results posted
• Immunity to Serotype 19A Streptococcus Pneumoniae in Children Vaccinated With PCV10CompletedNCT04912297Results posted
• Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2CompletedNCT04887948Phase 3Results posted
• 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and TaiwanCompletedNCT04875533Phase 3Results posted
• Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (V116) in Japanese Adults (V116-002)CompletedNCT04665050Phase 1Results posted
• Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of AgeCompletedNCT04642079Phase 3Results posted
• Safety and Immunogenicity of V114 in Healthy Infants in South Korea (V114-036)CompletedNCT04633226Phase 3Results posted
• 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy InfantsCompletedNCT04546425Phase 3Results posted
• 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese InfantsCompletedNCT04530838Phase 3Results posted
• Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of AgeCompletedNCT04526574Phase 3Results posted
• Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-033)CompletedNCT04384107Phase 3Results posted
• 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy InfantsCompletedNCT04382326Phase 3Results posted
• 20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy InfantsCompletedNCT04379713Phase 3Results posted
• Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025)CompletedNCT04031846Phase 3Results posted
• Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026)CompletedNCT04016714Phase 3Results posted
• Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020)CompletedNCT03950856Phase 3Results posted
• Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE)CompletedNCT03950622Phase 3Results posted
• Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED)CompletedNCT03921424Phase 3Results posted
• Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)CompletedNCT03893448Phase 3Results posted
• Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024)CompletedNCT03885934Phase 3Results posted
• Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028)CompletedNCT03848065Phase 1Results posted
• Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal VaccinationCompletedNCT03835975Phase 3Results posted
• Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve AdultsCompletedNCT03828617Phase 3Results posted
• A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal VaccineCompletedNCT03803202Phase 1/2Results posted
• Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve AdultsCompletedNCT03760146Phase 3Results posted
• A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE)CompletedNCT03731182Phase 3Results posted
• A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)CompletedNCT03692871Phase 3Results posted
• A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)CompletedNCT03620162Phase 3Results posted
• A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)CompletedNCT03615482Phase 3Results posted
• A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Infants and Young ChildrenCompletedNCT03574389Phase 3Results posted
• A Safety And Immunogenicity Study Of A 13-valent Pneumococcal Conjugate Vaccine In Japanese Subjects Aged 6 To 64 Years.CompletedNCT03571607Phase 3Results posted
• A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)CompletedNCT03565900Phase 3Results posted
• Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy InfantsTerminatedNCT03550313Phase 2Results posted
• A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)CompletedNCT03547167Phase 3Results posted
• Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy InfantsCompletedNCT03512288Phase 2Results posted
• A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)CompletedNCT03480802Phase 3Results posted
• A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)CompletedNCT03480763Phase 3Results posted
• A Trial To Evaluate A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults 50-85 Years Of AgeCompletedNCT03313050Phase 2Results posted
• Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of AgeCompletedNCT03313037Phase 2Results posted
• Immunization To Prevent Acute COPD ExacerbationsTerminatedNCT03276754Results posted
• A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)CompletedNCT02987972Phase 2Results posted
• Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary PathologyCompletedNCT02787863Phase 4Results posted
• Enhancing a Sustainable Pharmacy-based Immunization Program in Two StatesCompletedNCT02615470Not applicableResults posted
• Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007)CompletedNCT02573181Phase 2Results posted
• Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)CompletedNCT02547649Phase 2Results posted
• A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005)CompletedNCT02531373Phase 1/2Results posted
• Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, InfantsCompletedNCT02308540Phase 1/2Results posted
• System Alignment for VaccinE Delivery (SAVED): Improving Rates of Influenza and Pneumococcal Vaccination Through Patient Outreach, Improved Medical Record Accuracy and Targeted Physician AlertsCompletedNCT02266277Not applicableResults posted
• Revaccination With PNEUMOVAX™ 23 in Older Japanese Adults (V110-902)CompletedNCT02260882Phase 4Results posted
• Evaluation of the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Participants 50 Years of Age and Older (V110-029)CompletedNCT02225587Phase 3Results posted
• Nasopharyngeal Carriage Study in Healthy Kenyan ToddlersCompletedNCT02146365Results posted
• Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.CompletedNCT02124161Phase 4Results posted
• Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004)CompletedNCT02037984Phase 1/2Results posted
• Post Market Surveillance to Observe Safety of Prevenar13™ in AdultsCompletedNCT01834222Results posted
• Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine (Synflorix™) When Administered to Children Who Are at an Increased Risk of Pneumococcal InfectionCompletedNCT01746108Phase 3Results posted
• A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumovax™ 23 (V110) in Participants From the Russian Population (V110-018)CompletedNCT01734239Phase 3Results posted
• A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide VaccineCompletedNCT01654263Phase 2Results posted
• The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002)CompletedNCT01513551Phase 2Results posted
• 13-valent Pneumococcal Conjugate Vaccine Study in Adults => 50 Years of Age in MexicoCompletedNCT01432262Phase 3Results posted
• Safety Surveillance of Pneumococcal 13-valent Conjugate Vaccine Among FilipinosCompletedNCT01396434Results posted

← Pneumococcal Infections overview